234 related articles for article (PubMed ID: 37503786)
1. Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes.
Affolter A; Liebel K; Tengler L; Seiz E; Tiedtke M; Azhakesan A; Schütz J; Theodoraki MN; Kern J; Ruder AM; Fleckenstein J; Weis CA; Bieback K; Kramer B; Lammert A; Scherl C; Rotter N; Ludwig S
Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37503786
[TBL] [Abstract][Full Text] [Related]
2. PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling.
Zheng A; Li F; Chen F; Zuo J; Wang L; Wang Y; Chen S; Xiao B; Tao Z
Oncol Rep; 2019 May; 41(5):2833-2843. PubMed ID: 30864729
[TBL] [Abstract][Full Text] [Related]
3. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.
Weed DT; Zilio S; Reis IM; Sargi Z; Abouyared M; Gomez-Fernandez CR; Civantos FJ; Rodriguez CP; Serafini P
Front Immunol; 2019; 10():1206. PubMed ID: 31214178
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
5. Elevated exosomal lysyl oxidase like 2 is a potential biomarker for head and neck squamous cell carcinoma.
Sanada T; Islam A; Kaminota T; Kirino Y; Tanimoto R; Yoshimitsu H; Yano H; Mizuno Y; Okada M; Mitani S; Ugumori T; Tanaka J; Hato N
Laryngoscope; 2020 May; 130(5):E327-E334. PubMed ID: 31219623
[TBL] [Abstract][Full Text] [Related]
6. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.
Hernandez AL; Young CD; Bian L; Weigel K; Nolan K; Frederick B; Han G; He G; Devon Trahan G; Rudolph MC; Jones KL; Oweida AJ; Karam SD; Raben D; Wang XJ
Clin Cancer Res; 2020 Jun; 26(12):3058-3070. PubMed ID: 32139402
[TBL] [Abstract][Full Text] [Related]
8. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
[TBL] [Abstract][Full Text] [Related]
9. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
Bhatia S; Sharma J; Bukkapatnam S; Oweida A; Lennon S; Phan A; Milner D; Uyanga N; Jimeno A; Raben D; Somerset H; Heasley L; Karam SD
Clin Cancer Res; 2018 Sep; 24(18):4539-4550. PubMed ID: 29848571
[No Abstract] [Full Text] [Related]
11. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
12. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
[TBL] [Abstract][Full Text] [Related]
13. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
[TBL] [Abstract][Full Text] [Related]
14. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
15. Isolation and analysis of tumor‑derived extracellular vesicles from head and neck squamous cell carcinoma plasma by galectin‑based glycan recognition particles.
Benecke L; Chiang DM; Ebnoether E; Pfaffl MW; Muller L
Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36129151
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling.
Cui B; Chen J; Luo M; Wang L; Chen H; Kang Y; Wang J; Zhou X; Feng Y; Zhang P
Int J Oncol; 2020 Apr; 56(4):909-920. PubMed ID: 32319563
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S
Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
[TBL] [Abstract][Full Text] [Related]
19. Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC.
Rong C; Muller MF; Xiang F; Jensen A; Weichert W; Major G; Plinkert PK; Hess J; Affolter A
Br J Cancer; 2020 Jul; 123(2):288-297. PubMed ID: 32424150
[TBL] [Abstract][Full Text] [Related]
20. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
